International Women's Day: Addressing women's health in emerging markets
Friday 8th March 2019 marks International Women's Day, a global day of action aimed at accelerating gender equality and improving women's health. Asia-Pacific Director Pei Li Teh reflects on why this is such an important issue in emerging markets.
International Women’s Day is a commemoration of the social, economic, and cultural achievements of women around the world. Furthermore, the day marks a global call to action for accelerating gender parity by improving women’s access to education and quality, affordable healthcare. Since its inception in 1909, International Women’s Day has made tremendous progress to advance gender equality. Nevertheless, figures show that globally, women’s health indicators still lag behind those of men in many aspects.
How buyer insights supported the development of an effective market strategy
Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to understand how new medicines are added to the guidelines and how they are evaluated and funded. They also needed to gain an understanding of stakeholders’ reactions to their product, the drivers and barriers to use and expectations regarding pricing.
In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?
The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global health landscape through bilateral programs, health partnerships, and the support of multilateral organisations, as well as influencing global health policy and international health research. Its future has come under increasing scrutiny following the UK referendum result in favour of leaving the EU last year, and again in the wake of last month’s general election result.
Cool heads in a crisis?
Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics
First there was Ebola and now there is Zika; two official World Health Organization (WHO) Public Health Emergencies of International Concern (PHEIC) within as many years. Whenever global health crises such as these emerge, the pharmaceutical industry comes under intense scrutiny for not having an immediate solution available. Part of the problem is that prevention is not always financially viable; the substantial R&D costs of developing vaccines or treatments for all known and potential threats that may or may not one day develop into global pandemics is not a feasible burden for the industry to carry alone.
Qualitative research with payers in low and middle income countries
Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in low and middle income countries where patients self-pay for healthcare.
They also wanted to obtain a deep understanding of the groups of patients for whom self-pay is an issue and the sources of public funding that could potentially be leveraged. Our findings would complement market access considerations and point the way forward to a self-pay strategy that would maximise the potential for our client’s product.